<div class="description">
<p>Bisphosphonate-associated osteonecrosis of the jaws<br>Lieutenant Commander Aaron P. Sarathy, DC, USN, and Commander Sidney L. Bourgeois, Jr., DC, USN<br><br>Introduction<br>“Oral complications resulting from drug therapy and medical procedures have been an important, challenging subject for clinicians and researchers interested in oral disease for decades.” Chemical or pharmacologic agent involvement in the development of necrosis of the jaws is not a new phenomenon. The use of yellow phosphorus in matchmaking in the 19th century led to a condition known as “phossy jaw”. Today, clinicians are faced with another entity causing necrosis of the jaws with a similar appearance to that of “phossy jaw.” Many cancer patients with osteolytic processes (e.g. multiple myeloma, prostate cancer, breast cancer) are being treated with bisphosphonate medications for the skeletal complications and hypercalcemia of malignancy. These medications are also being used in the prevention of osteoporosis.
</p>
<br>Subjects: Bisphosphonate-Associated Osteonecrosis of the Jaw; Osteoporosis; Phosphorus</div>
<div class="fn value">
U.S. Navy. Naval Postgraduate Dental School</div>
<dl><dd><a rel="nofollow" class="external free" href="https://archive.org/details/05001BisphosphonateAssociatedOsteonecrosisOfTheJaws">https://archive.org/details/05001BisphosphonateAssociatedOsteonecrosisOfTheJaws</a></dd>
<dd><a rel="nofollow" class="external free" href="https://archive.org/download/05001BisphosphonateAssociatedOsteonecrosisOfTheJaws/05_-_001_Bisphosphonate-associated%20osteonecrosis%20of%20the%20jaws.pdf">https://archive.org/download/05001BisphosphonateAssociatedOsteonecrosisOfTheJaws/05_-_001_Bisphosphonate-associated%20osteonecrosis%20of%20the%20jaws.pdf</a></dd></dl>